| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.26 M USD | -11.41 M USD | -49.48 M USD | -65.07 M USD | -53.67 M USD | -37.32 M USD | -33.58 M USD | -19.24 M USD | -12.95 M USD | -4.13 M USD | — |
| Depreciation & Amortization | 34000 USD | 671000 USD | 1.86 M USD | 2.72 M USD | 2.17 M USD | 1.68 M USD | 1.26 M USD | 630000 USD | 2000 USD | 0 USD | — |
| Stock-Based Compensation | 129000 USD | -450000 USD | 568000 USD | 2.28 M USD | 3.31 M USD | 2.99 M USD | 2.66 M USD | 4.96 M USD | 2.01 M USD | 0 USD | — |
| Capital Expenditures | 1.17 M USD | 0 USD | 64000 USD | 2.71 M USD | 3.99 M USD | 1.93 M USD | 2.35 M USD | 6.87 M USD | 424000 USD | — | — |
| Cash Flow from Investing | 1.17 M USD | 0 USD | 5.89 M USD | -2.95 M USD | -5.37 M USD | -4.41 M USD | 13.91 M USD | 557000 USD | -29.05 M USD | 0 USD | — |
| Cash Flow from Financing | 14.53 M USD | 11.27 M USD | -26.08 M USD | 34.06 M USD | 70.85 M USD | 78.12 M USD | 65.12 M USD | 181000 USD | 49.98 M USD | 31.63 M USD | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -5.26 M USD | -11.41 M USD | -49.54 M USD | -67.78 M USD | -57.65 M USD | -39.24 M USD | -35.93 M USD | -26.11 M USD | -13.37 M USD | — | — |
Mustang Bio Inc. is a biotechnology company specializing in the development and commercialization of innovative and targeted therapies in the field of oncology. Its primary function is to advance the treatment of various cancers and genetic diseases through proprietary cell and gene therapies. Mustang Bio focuses on leveraging its scientific expertise to create therapies that specifically target cancer cells, hence improving treatment outcomes while minimizing side effects. The company’s research and development efforts have led to a robust pipeline, particularly concentrating on CAR-T cell therapies and gene therapies. Operating within the dynamic and rapidly evolving biotechnology industry, Mustang Bio plays a crucial role in addressing unmet medical needs, bringing transformative therapies from the laboratory to the clinic. By collaborating with academic institutions and a network of research partners, Mustang Bio enhances its capabilities in developing next-generation therapies. The company's contributions to the biotech sector underline its importance in bringing cutting-edge medical solutions to market, potentially transforming patient care and offering new hope in the treatment of life-threatening diseases.